(Lung Cancer) Is Ivesa Effective?

On March 31, 2022, ARRIVENT announced the efficacy and safety results from the FURLONG Phase III clinical trial of the EGFR tyrosine kinase inhibitor Ivesa (furmonertinib) as first-line treatment for patients with previously untreated metastatic or locally advanced EGFR mutation-positive non-small cell lung cancer (NSCLC).

The FURLONG Phase III trial was an international multicenter, randomized, placebo-controlled trial. Patients with previously untreated metastatic or locally advanced EGFR mutation-positive NSCLC were randomized to either the Ivesa group or the IRESSA (gefitinib) group as first-line treatment. The primary endpoint was progression-free survival (PFS).

At a median follow-up of 21.0 months, the primary endpoint median PFS was: Ivesa group 20.8 months vs. IRESSA group 11.1 months — compared to IRESSA, the Ivesa group showed a 56% reduction in the risk of disease progression or death.

The median treatment duration was 18.3 months for the Ivesa group vs. 11.2 months for the IRESSA group. Grade 3 or higher adverse events were: Ivesa group 11% vs. IRESSA group 18%.

Based on the trial results, the press release summarized: EGFR-positive NSCLC patients receiving Ivesa as first-line treatment showed significantly improved outcomes compared to first-generation EGFR inhibitors.

Source: https://arrivent.com/ivesa-demonstrates-progression-free-survival-of-over-20-months-in-first-line-setting-for-egfr-mutated-advanced-nsclc/

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer